CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 36 enrolled
Drug / intervention
Ombitasvir/Paritaprevir/Ritonavir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02216422
NCT02216422Phase 3Completed
CompareCT.gov

An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (Turquoise-IV)

AbbVie·interventional·Posted Aug 15, 2014·Updated Jun 29, 2016

In Brief

A Phase 3 clinical trial evaluating Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, and 1 other intervention for Chronic Hepatitis C Virus (HCV) Infection. Completed, enrolled 36 participants.

Detailed Summary

This was a multicenter study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir co-administered with ribavirin (RBV) for 12 weeks in treatment naïve and pegylated-interferon alfa-2a or alfa-2b (pegIFN)/RBV treatment-experienced, cirrhotic HCV genotype 1b-infected adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Virus (HCV) Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 15, 2014
Enrollment StartSep 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.9 years ago

Interventions

Ombitasvir/Paritaprevir/Ritonavirdrug

Tablet; paritaprevir co-formulated with ritonavir and ombitasvir

Dasabuvirdrug

Tablet

Ribavirin (RBV)drug

Tablet